Optimal duration of whole body hyperthermia when combined with cis-diamminedichloroplatinum(II)

International Journal of Oncology

Volumn 10, Issue 2, 1997, Pages 329-332

  Makino, Masato ^a,b   Ohno, Shinji ^a,c   Sakaguchi, Yoshihisa ^a,c   Kaneko, Tetsuya ^a,b   Strebel, Frederick R ^a   Jenkins, Gaye ^a   Bull, Joan M C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b TOTTORI UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

cis diamminedichloroplatinum(II); duration of heat; renal toxicity; therapeutic gain; whole body hyperthermia

Indexed keywords

CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; FEMALE; FIBROSARCOMA; HYPERTHERMIA; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031059323     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.2.329     Document Type: Article

References (24)

1. Bull JMC: An update on the anticancer effects of a combination of chemotherapy and hyperthermia. Cancer Res 44 (Suppl): 4853-4856, 1984.
2. Pettigrew WT, Galt JM, Ludgate CM and Smith AN: Clinical effects of whole-body hyperthermia in advanced malignancy. Br Med J 4: 679-682, 1974.
3. Larkin JM, Edwards WS, Smith DE and Clark PJ: Systemic thermotherapy: description of a method and physiologic tolerance in clinical subjects. Cancer 40: 3155-3159, 1977.
4. Hahn GM: Potential for drugs and hyperthermia. Cancer Res 39: 2264-2268, 1979.
5. Hrushesky WJM, Levi FA, Halbey F and Kennedy BJ: Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res 42: 945-949, 1982.
6. Wondergem J, Bulger RE, Strebel FR, Newman RA, Travis EL, Stephens LC and Bull JMC: Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Res 48: 440-446, 1988.
7. Rotstein LE, Daly J and Rossa P: Systemic thermochemotherapy in a rat model. Can J Surg 26: 113-116, 1983.
8. Ward JM, Young DM, Fauvi KA, Wolpert MK, Davis R and Guarino AM: Comparative nephrotoxicity of platinum cancer chemotherapeutic agents. Cancer Treatment Rep 60: 1657-1678, 1976.
9. Baba H, Siddik ZH, Strebel FR, Jenkins GN and Bull JMC: Increased therapeutic gain of combined cis-diamminedichloroplatinum(II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Cancer Res 49: 7041-7044, 1989.
10. Overgaard J and Suit HD: Time-temperature relationship in hyperthermic treatment of malignant and normal tissue in vivo. Cancer Res 39: 3248-3253, 1979.
11. Barlogie B, Corry PM, Yip E, Lippman L, Jonston DA, Khalil K, Tenczynski TF, Reilly E, Lawson R, Dosik G, Rigor B, Hankenson R and Freireich EJ: Total-body hyperthermia with and without chemotherapy for advanced human neoplasms. Cancer Res 39: 1481-1489, 1979.
12. Engelhardt R, Muller U, Weth-Simon R, Neumann HA and Lehr GW: Treatment of disseminated malignant melanoma with cisplatin in combination with whole-body hyperthermia and doxorubicin. Int J Hyperthermia 6: 511-515, 1990.
13. Bull JMC, Cronau LH, Newman BM, Jabboury K, Allen SJ, Ohno S and Smith T: Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) combined with 1-3-Bis(2-chloroethyl)-1-nitrosourea (BCNU). Int J Hyperthermia 8: 297-304, 1992.
14. Barlogie B, Corry PM and Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis-dichlordiammineplatinum(II) and mitomycin C. Cancer Res 40: 1165-1168, 1980.
15. Wallner KE, De Gregorio MW and Li GC: Hyperthermic potentiation of cytotoxicity in Chinese hamster ovary cells resistant to the drugs. Cancer Res 46: 6242-6245, 1986.
16. Marmor JB: Interaction of hyperthermia and chemotherapy in animals. Cancer Res 39: 2269-2276, 1979.
17. Alberts DS, Peng Y-M, Chen H-SG, Moon TE, Cetas TC and Hoeschele JD: Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst 65: 455-461, 1980.
18. Meyn RE, Corry PM, Fletcher SE and Demetriades M: Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res 40: 1136-1139, 1980.
19. Zakiris EL, Dewhirst MW, Riviere JE, Hoopes PJ, Page RL and Oleson JR: Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 5: 1613-1620, 1987.
20. Wondergem J, Siddik ZH, Strebel FR and Bull JMC: Effect of whole body hyperthermia on cis-diamminedichloroplatinum(II)-induced antitumour activity and tissue Pt-distribution: do anaesthetics influence the therapeutic ratio? Eur J Cancer 29A: 549-554, 1993.
21. Bull JMC, Strebel F, Sunderland BA, Bulger RE, Edwards M, Siddik ZH and Newman RA: o-(β-Hydroxyethel)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment. Cancer Res 48: 2239-2244, 1988.
22. Sapareto SA, Hopwood LE, Dewey WC, Raju MR and Gray JW: Effects of hyperthermia on survival and progression of Chinese hamster ovary cells. Cancer Res 38: 393-400, 1978.
23. Choie DD, Longnecker DS and Del Campo AA: Acute and chronic cisplatin nephropathy in rats. Lab Invest 44: 397-402, 1981.
24. Urano M, Kahn J and Kenton LA: The effect of cis-diamminedichloroplatinum(II) treatment at elevated temperatures on murine fibrosarcoma, FSa-II. Int J Hyperthermia 6: 563-570, 1990.